Next, to unveil the inter-relationship between the dynamic IDO1 expression in the MLNs and the cancer-immune set point in individuals and to establish a PET imaging-guided precision medicine paradigm for cancer immunotherapy, we performed a longitudinal 11C-l-1MTrp PET imaging study throughout the entire treatment process in mice treated with l-1MTrp+CPA (figure 5A). The gene discussed is IDO1; the disease is cancer.